Clearstead Advisors’s MaxCyte MXCT Stock Holding History

Clearstead Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-97	Closed	-$154	–	3074
2025 Q3	$154	Buy	+97	New	+$169	﹤0.01%	2889

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clearstead Advisors's MXCT Position: Q4 2025 in Review

Clearstead Advisors sold out of MaxCyte (MXCT) in Q4 2025, closing a stake of 97 shares — an estimated $154 sold.

Clearstead Advisors first reported a position in MXCT in Q3 2025 and held it in 1 quarter. The position peaked at $154 in Q3 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q4 2025.

Clearstead Advisors reported no remaining MaxCyte position as of Q4 2025 after selling out during the quarter.
Clearstead Advisors sold 97 MaxCyte shares in Q4 2025, an estimated $154.
Clearstead Advisors first reported a position in MaxCyte in Q3 2025 and held it in 1 quarter.
Clearstead Advisors's MaxCyte position peaked at $154 in Q3 2025.
112 funds tracked by Wall St. Rank held MaxCyte as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.